| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ... New England journal of medicine 369 (18), 1691-1703, 2013 | 6719 | 2013 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ... New England Journal of Medicine 367 (18), 1694-1703, 2012 | 3128 | 2012 |
| Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1 … JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, ... The Lancet 398 (10297), 314-324, 2021 | 1018 | 2021 |
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial GS Falchook, GV Long, R Kurzrock, KB Kim, TH Arkenau, MP Brown, ... The Lancet 379 (9829), 1893-1901, 2012 | 1013 | 2012 |
| First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement J Tabernero, GI Shapiro, PM LoRusso, A Cervantes, GK Schwartz, ... Cancer discovery 3 (4), 406-417, 2013 | 775 | 2013 |
| Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study AB Apolo, JR Infante, A Balmanoukian, MR Patel, D Wang, K Kelly, ... Journal of Clinical Oncology 35 (19), 2117-2124, 2017 | 630 | 2017 |
| Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial GS Falchook, KD Lewis, JR Infante, MS Gordon, NJ Vogelzang, ... The lancet oncology 13 (8), 782-789, 2012 | 606 | 2012 |
| Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial MR Patel, J Ellerton, JR Infante, M Agrawal, M Gordon, R Aljumaily, ... The Lancet Oncology 19 (1), 51-64, 2018 | 598 | 2018 |
| Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study DF McDermott, JA Sosman, M Sznol, C Massard, MS Gordon, O Hamid, ... Journal of Clinical Oncology 34 (8), 833-842, 2016 | 583 | 2016 |
| Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial JR Infante, LA Fecher, GS Falchook, S Nallapareddy, MS Gordon, ... The lancet oncology 13 (8), 773-781, 2012 | 580 | 2012 |
| Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF … KB Kim, R Kefford, AC Pavlick, JR Infante, A Ribas, JA Sosman, ... Journal of Clinical Oncology 31 (4), 482-489, 2013 | 559 | 2013 |
| Targeting CDK4/6 in patients with cancer E Hamilton, JR Infante Cancer treatment reviews 45, 129-138, 2016 | 474 | 2016 |
| Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ... Journal of Clinical Oncology 35 (34), 3851-3858, 2017 | 459 | 2017 |
| Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma JR Infante, H Matsubayashi, N Sato, J Tonascia, AP Klein, TA Riall, C Yeo, ... Journal of Clinical Oncology 25 (3), 319-325, 2007 | 455 | 2007 |
| Phase I dose-escalation study of JNJ-42756493, an oral pan–fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors J Tabernero, R Bahleda, R Dienstmann, JR Infante, A Mita, A Italiano, ... Journal of clinical oncology 33 (30), 3401-3408, 2015 | 397 | 2015 |
| First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study RJ Sullivan, JR Infante, F Janku, DJL Wong, JA Sosman, V Keedy, ... Cancer discovery 8 (2), 184-195, 2018 | 378 | 2018 |
| Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma KD Courtney, JR Infante, ET Lam, RA Figlin, BI Rini, J Brugarolas, ... Journal of Clinical Oncology 36 (9), 867-874, 2018 | 356 | 2018 |
| Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. R Kefford, H Arkenau, MP Brown, M Millward, JR Infante, GV Long, ... Journal of Clinical Oncology 28 (15_suppl), 8503-8503, 2010 | 353 | 2010 |
| A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma … JR Infante, BG Somer, JO Park, CP Li, ME Scheulen, SM Kasubhai, ... European journal of cancer 50 (12), 2072-2081, 2014 | 341 | 2014 |
| Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib GV Long, JS Weber, JR Infante, KB Kim, A Daud, R Gonzalez, JA Sosman, ... Journal of Clinical Oncology 34 (8), 871-878, 2016 | 333 | 2016 |
